Paula A. Johnson's most recent trade in Maze Therapeutics Inc. was a trade of 36,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Aug. 13, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Maze Therapeutics Inc | Paula A. Johnson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Aug 2026 | 36,000 | 36,000 | - | - | Stock Option (Right to Buy) | |
| Johnson & Johnson | Paula A. Johnson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Apr 2026 | 975 | 5,359 | - | - | Deferred Share Units | |
| Johnson & Johnson | Paula A. Johnson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Apr 2025 | 1,316 | 4,265 | - | - | Deferred Share Units | |
| Johnson & Johnson | Paula A. Johnson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Apr 2024 | 1,385 | 2,858 | - | - | Deferred Share Units | |
| Johnson & Johnson | Paula A. Johnson | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 23 Aug 2023 | 11 | 89 (0%) | 0% | 0 | Common Stock | |
| Johnson & Johnson | Paula A. Johnson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Apr 2023 | 1,429 | 1,429 | - | - | Deferred Share Units |